Theravance Halves Workforce, Shuts R&D to Save $70M After Trial Failure
Theravance Biopharma will discontinue its ampreloxetine program and cut workforce by 50% after its Phase III CYPRESS trial failed the OHSA primary endpoint in orthostatic hypotension. The restructuring carries $5–7 million in severance costs, cuts $70 million in operating expenses and shifts value to its 35% stake in Yupelri and Trelegy COPD revenues.
1. Phase III Trial Failure
Theravance’s CYPRESS study (NCT05696717) in multiple system atrophy patients failed to improve the Orthostatic Hypotension Symptom Assessment composite score at eight weeks, missing its primary OHSA endpoint. Secondary measures of blood pressure, heart rate and norepinephrine confirmed biological activity but showed no clinical benefit, leading to discontinuation of ampreloxetine development.
2. Restructuring Plan
Following the trial failure, Theravance will wind down its R&D organization and cut approximately half of its workforce over the next two quarters. The company expects one-time severance expenses of $5–7 million while achieving about $70 million in annual operating expense savings.
3. Future Focus on Marketed Assets
Post-restructuring, Theravance’s value will derive from marketed COPD therapies: a 35% interest in the nebulised LAMA Yupelri, generating $60–70 million of annual cash flow, and co-promoted Trelegy, a once-daily ICS/LAMA/LABA dry-powder inhaler developed with GSK.
4. Market Reaction
Nasdaq-traded shares tumbled 26.33% on the day of the announcement, falling from $18.95 to $13.96, reflecting investor concern over pipeline setbacks and workforce reductions.